Farnesoid X receptor: From medicinal chemistry to clinical applications

Future Medicinal Chemistry

Volumn 4, Issue 7, 2012, Pages 877-891

  Fiorucci, Stefano ^a   Mencarelli, Andrea ^a   Distrutti, Elenora ^b   Zampella, Angela ^c  

^a UNIVERSITY OF PERUGIA   (Italy)

^b SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3 [2 [2 CHLORO 4 [3 (2,6 DICHLOROPHENYL) 5 ISOPROPYL 4 ISOXAZOLYLMETHOXY]PHENYL]VINYL]BENZOIC ACID; BILE ACID; CELL NUCLEUS RECEPTOR; CHENODEOXYCHOLIC ACID; CHOLIC ACID; DEOXYCHOLIC ACID; FARNESOID X RECEPTOR; HORMONE RECEPTOR BLOCKING AGENT; ISOPROTEIN; LITHOCHOLIC ACID; N (2,2,2 TRIFLUOROETHYL) N [4 [2,2,2 TRIFLUORO 1 HYDROXY 1 (TRIFLUOROMETHOXY)ETHYL]PHENYL]BENZENESULFONAMIDE; STEROID; TUROFEXORATE ISOPROPYL; URSODEOXYCHOLIC ACID;

BILE ACID METABOLISM; CHEMICAL ANALYSIS; CHOLESTASIS; CHOLESTATIC HEPATITIS; CLINICAL CHEMISTRY; DRUG TARGETING; GENE EXPRESSION; GLUCOSE HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; LIGAND BINDING; LIPID METABOLISM; METABOLIC DISORDER; NONHUMAN; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; RECEPTOR BINDING; REVIEW; TARGET CELL; TREATMENT INDICATION;

ANIMALS; ATHEROSCLEROSIS; BILE ACIDS AND SALTS; CHOLESTASIS; DIABETES MELLITUS, TYPE 2; DRUG DISCOVERY; HUMANS; LIGANDS; LIVER; LIVER DISEASES; METABOLIC DISEASES; PROTEIN CONFORMATION; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 84861088470     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.12.41     Document Type: Review

References (41)

1. Mukherjee S, Lindell DM, Berlin AA et al. IL-17-induced pulmonary pathogenesis during respiratory viral infection and exacerbation of allergic disease. Am. J. Pathol. 179(1), 248-258 (2011
2. Lukacs NW. Role of chemokines in the pathogenesis of asthma. Nat. Rev. Immunol. 1(2), 108-116 (2001
3. Pelletier M, Maggi L, Micheletti A et al. Evidence for a cross-Talk between human neutrophils and Th17 cells. Blood 115(2), 335- 343 (2010
4. Wilson RH, Whitehead GS, Nakano H, Free ME, Kolls JK, Cook DN. Allergic sensitization through the airway primes Th17-dependent neutrophilia and airway hyperresponsiveness. Am. J. Respir. Crit. Care Med. 180(8), 720-730 (2009
5. Ely LK, Fischer S, Garcia KC. Structural basis of receptor sharing by interleukin 17 cytokines. Nat. Immunol. 10(12), 1245-1251 (2009
6. Gaffen SL. Structure and signalling in the IL-17 receptor family. Nat. Rev. Immunol. 9(8), 556-567 (2009
7. Song X, Zhu S, Shi P et al. IL-17RE is the functional receptor for IL-17C and mediates mucosal immunity to infection with intestinal pathogens. Nat. Immunol. 12(12), 1151-1158 (2011
8. Rickel EA, Siegel LA, Yoon BR et al. Identification of functional roles for both IL-17RB and IL-17RA in mediating IL-25-induced activities. J. Immunol. 181(6), 4299-4310 (2008
9. Fort MM, Cheung J, Yen D et al. IL-25 induces IL-4, IL-5, and IL-13 and Th2-Associated pathologies in vivo. Immunity 15(6), 985-995 (2001
10. Kaiko GE, Phipps S, Angkasekwinai P, Dong C, Foster PS. NK cell deficiency predisposes to viral-induced Th2-Type allergic inflammation via epithelial-derived IL-25. J. Immunol. 185(8), 4681-4690 (2010
11. Ballantyne SJ, Barlow JL, Jolin HE et al. Blocking IL-25 prevents airway hyperresponsiveness in allergic asthma. J. Allergy Clin. Immunol. 120(6), 1324-1331 (2007
12. Khader SA, Gaffen SL, Kolls JK. Th17 cells at the crossroads of innate and adaptive immunity against infectious diseases at the mucosa. Mucosal Immunol. 2(5), 403-411 (2009
13. Fujie H, Niu K, Ohba M et al. A distinct regulatory role of Th17 cytokines IL-17A and IL-17F in chemokine secretion from lung microvascular endothelial cells. Inflammation doi:101007/s1075301194190 (2012) (Epub ahead of print
14. Mjosberg JM, Trifari S, Crellin NK et al. Human IL-25-And IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161. Nat. Immunol. 12(11), 1055-1062 (2011
15. Lee JW, Wang P, Kattah MG et al. Differential regulation of chemokines by IL-17 in colonic epithelial cells. J. Immunol. 181(9), 6536-6545 (2008
16. Zhao Y, Yang J, Gao YD, Guo W. Th17 immunity in patients with allergic asthma. Int. Arch. Allergy Immunol. 151(4), 297-307 (2010
17. McKinley L, Alcorn JF, Peterson A et al. TH17 cells mediate steroid-resistant airway inflammation and airway hyperresponsiveness in mice. J. Immunol. 181(6), 4089-4097 (2008
18. Hvid M, Vestergaard C, Kemp K, Christensen GB, Deleuran B, Deleuran M. IL-25 in atopic dermatitis: A possible link between inflammation and skin barrier dysfunction? J. Invest. Dermatol. 131(1), 150-157 (2011
19. Terrier B, Bieche I, Maisonobe T et al. Interleukin-25: A cytokine linking eosinophils and adaptive immunity in Churg-Strauss syndrome. Blood 116(22), 4523-4531 (2010
20. Corrigan CJ, Wang W, Meng Q et al. Allergen-induced expression of IL-25 and IL-25 receptor in atopic asthmatic airways and late-phase cutaneous responses. J. Allergy Clin. Immunol. 128(1), 116-124 (2011
21. Busch-Petersen J. Small molecule antagonists of the CXCR2 and CXCR1 chemokine receptors as therapeutic agents for the treatment of inflammatory diseases. Curr. Top. Med. Chem. 6(13), 1345-1352 (2006
22. Hwang SY, Kim JY, Kim KW et al. IL-17 induces production of IL-6 and IL-8 in rheumatoid arthritis synovial fibroblasts via NF-kB-And PI3-kinase/Akt- dependent pathways. Arthritis Res. Ther. 6(2), R120-R128 (2004
23. Laan M, Cui ZH, Hoshino H et al. Neutrophil recruitment by human IL-17 via C-X-C chemokine release in the airways. J. Immunol. 162(4), 2347-2352 (1999
24. Sahin H, Berres ML, Wasmuth HE. Therapeutic potential of chemokine receptor antagonists for liver disease. Expert Rev. Clin. Pharmacol. 4(4), 503-513 (2011
25. Lebre MC, Vergunst CE, Choi IY et al. Why CCR2 and CCR5 blockade failed and why CCR1 blockade might still be effective in the treatment of rheumatoid arthritis. PLoS ONE 6(7), e21772 (2011
26. Struthers M, Pasternak A. CCR2 antagonists. Curr. Top. Med. Chem. 10(13), 1278-1298 (2010
27. Mencarelli A, Renga B, Distrutti E et al. Antiatherosclerotic effect of farnesoid X receptor. Am. J. Physiol. Heart Circ. Physiol. 296, H272-H281 (2009
28. Hartman HB, Gardell SJ, Petucci CJ et al. Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR-/- And apoE-/- mice. J. Lipid. Res. 50, 1090-1100 (2009
29. Prawitt J, Abdelkarim M, Stroeve JH et al. Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity. Diabetes 60(7), 1861-1871 (2011
30. Watanabe M, Horai Y, Houten SM et al. Lowering bile acid pool size with a synthetic FXR agonist induces obesity and diabetes through reduced energy expenditure. J. Biol. Chem. 286(30), 26913-26920 (2011). Adverse metabolic effects could develop in response to chronic use of FXR agonists in the treatment of rodent model of obesity.
31. Renga B, Mencarelli A, Vavassori P et al The bile acid sensor FXR regulates insulin transcription and secretion. Biochim. Biophys. Acta 1802, 363-372 (2010
32. Popescu IR, Helleboid-Chapman A et al. The nuclear receptor FXR is expressed in pancreatic beta-cells and protects human islets from lipotoxicity. FEBS Lett. 584, 2845-2851 (2010
33. Farrell GC. Nonalcoholic fatty liver disease: From steatosis to cirrhosis. Hepatology 43, S99-S112 (2006
34. Belfort R, Harrison SA, Brown K et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N. Engl. J. Med. 355, 2297-2307 (2006
35. Cipriani S, Mencarelli A, Chini MG et al. The bile acid receptor GPBAR-1 (TGR5) modulates integrity of intestinal barrier and immune response to experimental colitis. PLoS ONE 6, e25637 (2011
36. Henry RR, Mudaliar S, Morrow L et al. Farnesoid-X receptor agonists: A new therapeutic class for diabetes and fatty liver disease? The first FXR therapeutic study in diabetes. Presented at: Annual Meeting of the American Diabetes Association. Chicago, IL, USA, 6-9 June 2007.
37. Sanyal AJ, Mudaliar S, Henry RR et al. A new therapy for nonalcoholic fatty liver disease and diabetes? Int-747 - the first FXR hepatic therapeutic study. Hepatology 50, 389A-390A (2009). First report describing the potential therapeutic role of an FXR agonist in the treatment of non-Alcoholic fatty acid liver disease patients.
38. Burris TP, Montrose C, Houck KA et al. The hypolipidemic natural product guggulsterone is a promiscuous steroid receptor ligand. Mol. Pharmacol. 67, 948-954 (2005
39. De Marino S, Ummarino R, D'Auria MV et al. Theonellasterols and conicasterols from Theonella swinhoei. Novel marine natural ligands for human nuclear receptors. J. Med. Chem. 54, 3065-3075 (2011). Study reporting the identification of theonellasterol G as the first FXR modulator and pregnane X receptor ligand so far identified, highlighting its pharmacological potential in the treatment of liver disorders, such as obstructive cholestasis.
40. Sepe V, Bifulco G, Renga B et al. Discovery of sulfated sterols from marine invertebrates as a new class of marine natural antagonists of farnesoid-X-receptor. J. Med. Chem. 54, 1314-1320 (2011
41. Renga B, Mencarelli A, D'Amore C et al. Discovery that theonellasterol a marine sponge sterol is a highly selective FXR antagonist that protects against liver injury in cholestasis. PLoS ONE 7(1), e30443 (2012). First demonstration that specific FXR antagonists exist and could be of pharmacological relevance